TY - JOUR
T1 - The gut microbiota and diabetes
T2 - research, translation, and clinical applications – 2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum
AU - Byndloss, Mariana
AU - Devkota, Suzanne
AU - Duca, Frank
AU - Niess, Jan Hendrik
AU - Nieuwdorp, Max
AU - Orho-Melander, Marju
AU - Sanz, Yolanda
AU - Tremaroli, Valentina
AU - Zhao, Liping
N1 - Publisher Copyright:
© American Diabetes Association and the European Association for the Study of Diabetes 2024.
PY - 2024/9
Y1 - 2024/9
N2 - This article summarises the state of the science on the role of the gut microbiota (GM) in diabetes from a recent international expert forum organised by Diabetes, Diabetes Care, and Diabetologia, which was held at the European Association for the Study of Diabetes 2023 Annual Meeting in Hamburg, Germany. Forum participants included clinicians and basic scientists who are leading investigators in the field of the intestinal microbiome and metabolism. Their conclusions were as follows: (1) the GM may be involved in the pathophysiology of type 2 diabetes, as microbially produced metabolites associate both positively and negatively with the disease, and mechanistic links of GM functions (e.g. genes for butyrate production) with glucose metabolism have recently emerged through the use of Mendelian randomisation in humans; (2) the highly individualised nature of the GM poses a major research obstacle, and large cohorts and a deep-sequencing metagenomic approach are required for robust assessments of associations and causation; (3) because single time point sampling misses intraindividual GM dynamics, future studies with repeated measures within individuals are needed; and (4) much future research will be required to determine the applicability of this expanding knowledge to diabetes diagnosis and treatment, and novel technologies and improved computational tools will be important to achieve this goal.
AB - This article summarises the state of the science on the role of the gut microbiota (GM) in diabetes from a recent international expert forum organised by Diabetes, Diabetes Care, and Diabetologia, which was held at the European Association for the Study of Diabetes 2023 Annual Meeting in Hamburg, Germany. Forum participants included clinicians and basic scientists who are leading investigators in the field of the intestinal microbiome and metabolism. Their conclusions were as follows: (1) the GM may be involved in the pathophysiology of type 2 diabetes, as microbially produced metabolites associate both positively and negatively with the disease, and mechanistic links of GM functions (e.g. genes for butyrate production) with glucose metabolism have recently emerged through the use of Mendelian randomisation in humans; (2) the highly individualised nature of the GM poses a major research obstacle, and large cohorts and a deep-sequencing metagenomic approach are required for robust assessments of associations and causation; (3) because single time point sampling misses intraindividual GM dynamics, future studies with repeated measures within individuals are needed; and (4) much future research will be required to determine the applicability of this expanding knowledge to diabetes diagnosis and treatment, and novel technologies and improved computational tools will be important to achieve this goal.
KW - Butyrate
KW - Faecal microbiota transplantation
KW - Gastrointestinal microbiota
KW - Gastrointestinal tract microbiology
KW - Gut microbiota
KW - Large intestine microbiota
KW - Metagenomics
KW - Microbiota metabolites
KW - Review
KW - Short-chain fatty acids
KW - Small intestine microbiota
UR - http://www.scopus.com/inward/record.url?scp=85196641458&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85196641458&partnerID=8YFLogxK
U2 - 10.1007/s00125-024-06198-1
DO - 10.1007/s00125-024-06198-1
M3 - Review article
C2 - 38910152
AN - SCOPUS:85196641458
SN - 0012-186X
VL - 67
SP - 1760
EP - 1782
JO - Diabetologia
JF - Diabetologia
IS - 9
ER -